Cardiovascular safety of orforglipron versus insulin glargine in adults with type 2 diabetes at increased cardiovascular risk (ACHIEVE-4): a phase 3, event-driven, randomised, open-label, non-inferiority, active comparator trial. (PubMed, Lancet) - Oct 1, 2026 - P3 | "In people with type 2 diabetes at increased cardiovascular risk, the cardiovascular safety of orforglipron was confirmed by demonstrating non-inferiority to insulin glargine for MACE-4. Gastrointestinal adverse events were the most frequent adverse event and most common reason for orforglipron treatment discontinuation with orforglipron, while clinically significant hypoglycaemia occurred less frequently with orforglipron than with insulin glargine. These findings support orforglipron as a potential once-daily, oral treatment option with established cardiovascular safety in people with type 2 diabetes and increased cardiovascular risk."
Head-to-Head • Journal • P3 data • Cardiovascular • Chronic Kidney Disease • Diabetes • Genetic Disorders • Metabolic Disorders • Myocardial Infarction • Nephrology • Obesity • Renal Disease • Severe Hypoglycemia • Type 2 Diabetes Mellitus
|
|
Carol Wysham; David Cox; Eric R Meskimen; Jiaxun Chen; Katherine R Tuttle; Klara R Klein; Lisa Ludwig; Max Denning; Melanie J Davies; Rong Liu; Wen-Shuo Wu
|